Lung transplantation in cystic fibrosis: Consensus conference statement

Chest

Volumn 113, Issue 1, 1998, Pages 217-226

  Yankaskas, James R ^a   Mallory Jr , George B ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Cystic fibrosis; Lung transplantation; Respiratory failure

Indexed keywords

AMPHOTERICIN B; CHICKENPOX VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; ITRACONAZOLE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

AUSTRALIA; CYSTIC FIBROSIS; EUROPE; HEALTH CARE ORGANIZATION; HEART LUNG TRANSPLANTATION; HUMAN; IMMUNIZATION; LUNG TRANSPLANTATION; MEDICAL PRACTICE; MEDICAL SPECIALIST; NORTH AMERICA; ORGAN DONOR; PATIENT REFERRAL; PATIENT SELECTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; TREATMENT CONTRAINDICATION;

EID: 0031973453     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.1.217     Document Type: Article

References (30)

1. Kotloff RM, Zuckerman JB. Lung transplantation for cystic fibrosis: special considerations. Chest 1996; 109:787-98
2. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187-91
3. Langnas AN, Duckworth RM, Stratta RJ, et al. Imported hepatic allografts: a single center experience. Transplant Proc 1990; 22:414-15
4. Hesse UJ, Berrevoet F, Pattyn P, et al. Organ sharing for shipped livers used as full-size, reduced, or split grafts. Transplant Proc 1996; 28:278-79
5. Murray JE. The first successful organ transplants in man. Scand J Immunol 1994; 39:4-9
6. Jnrim O, Shackleton CR, McDiarmid, et al. Living-donor liver transplantation at UCLA. Am J Surg 1995; 169:529-32
7. Starnes VA, Barr M, Cohen R, et al. Living donor lobar lung transplantation experience: intermediate results. J Thorac Cardiovasc Surg 1996; 112:1284-91
8. Starnes VA, Barr ML, Cohen RG. Lobar transplantation: indications, technique and outcome. J Thorac Cardiovasc Surg 1994; 108:403-11
9. Egan TM, Lambert CJ, Reddick R, et al. A strategy to increase the donor pool: use of cadaver lungs for transplantation. Ann Thorac Surg 1991; 52:1113-20
10. Roberts CS, D'Armini AM, Egan TM. Canine double-lung transplantation with cadaveric donors. J Thorac Cardiovasc Surg 1996; 112:577-83
11. Couetil JP, Grousset A, Benaim D, et al. Experimental model of pulmonary bipartition with bilateral lobe transplantation in dogs and application to clinical medicine. Chirurgie 1994; 120:512-17
12. Flume PA, Egan TM, Paradowski LJ, et al. Infectious complications of lung transplantation: impact of cystic fibrosis. Am J Respir Crit Care Med 1994; 149:1601-07
13. Snell GI, de Hoyos A, Krajden M, et al. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 1993; 103:466-71
14. Steinbach S, Sun L, Jiang R, et al. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med 1994; 331:981-87
15. Microbiology and Infectious Disease in Cystic Fibrosis, Consensus Conference. Concepts in care (vol V, section 1). Bethesda, Md: Cystic Fibrosis Foundation, 1994
16. Saiman L, Mehar F, Niu W, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with CF including candidates for transplant. Clin Infect Dis 1996; 23:532-37
17. Olivier KN, Yankaskas JR, Knowles KR. Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Semin Respir Infect 1996; 11:272-84
18. von Reyn CF, Green PA, McCormick D, et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative: an open study with M avium complex infections or tuberculosis. Clin Infect Dis 1994; 19:15-20
19. Lewiston N, King V, Umetsu D, et al. Cystic fibrosis patients who have undergone heart-lung transplantation benefit from maxillary sinus antrostomy and repeated sinus lavage. Transplant Proc 1991; 23:1207-08
20. Wong K, Roberts MC, Owens L, et al. Selective media for the quantitation of bacteria in cystic fibrosis sputum. J Med Microbiol 1984; 17:113-19
21. Garner JS. Hospital infection control practices advisory committee: guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996; 17:53-80
22. Madden B, Hodson ME, Tsang V, et al. Intermediate-term results of heart-lung transplantation for cystic fibrosis. Lancet 1992; 339:1583-87
23. Madden B, Kamalvand K, Chan CM, et al. The medical management of patients with cystic fibrosis following heart-lung transplantation. Eur Respir J 1993; 6:965-70
24. Prandota J. Drug deposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics. Pediatr Infect Dis J 1987; 17(suppl 1):29-67
25. deGroot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clin Pharmacokinet 1987; 13:228-53
26. Spino M. Pharmacokinetics of drugs in cystic fibrosis. Clin Rev Allergy 1991; 9:169-210
27. Kearns GL. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions. Ann Pharmacother 1993; 27:74-79
28. Tan KK, Trull AK, Hue KL, et al. Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome. Clin Pharmacol Ther 1993; 53:544-54
29. Squier HC, Ries AL, Kaplan RM, et al. Quality of well-being predicts survival in lung transplantation candidates. Am J Respir Crit Care Med 1995; 152:2032-36
30. Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. N Engl J Med 1995; 332:494-99